FBTIX Fees and Costs — Fidelity Advisor Biotechnology Fund, Class I
Data updated: 2026-10-13
The net expense ratio is 0.69%: a 0.68% management fee plus 0.01% other expenses. There are no sales loads or redemption fees. In fiscal 2026 the fund paid $673K in broker commissions, 0.0368% of average net assets, and portfolio turnover was 54%.
FBTIX Fees and Expenses
Annual operating expenses and sales charges of FBTIX. Prospectus, as of September 29, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 0.68% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.01% |
| Gross expense ratio | 0.69% |
| Fee waiver | — |
| Net expense ratio | 0.69% |
| Sales charges | |
|---|---|
| Max front load | 0.00% |
| Max deferred load | 0.00% |
| Redemption fee | — |
FBTIX Costs Over Time
On $10,000 invested in FBTIX, assuming 5% a year before costs, total costs come to $457 over 5 years, cutting the return by 0.76% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.69%) | $72 | $227 | $394 |
| Trading costs (broker commissions) | $4 | $12 | $21 |
| Lost growth on money paid in costs | $0 | $12 | $42 |
| Total costs | $76 | $251 | $457 |
| Value after costs | $10,424 | $11,326 | $12,306 |
| Impact on return, per year | 0.76% | 0.76% | 0.76% |
FBTIX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending July 31, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.0368%
- Total broker commissions: $673K
- Bought from dealers (principal trades, not a cost): $67.5M
- Portfolio turnover (prospectus): 54%
FBTIX Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| JPMORGAN CHASE and CO | $84K | 17.42% |
| JEFFERIES FINANCIAL GROUP INC | $76K | 15.78% |
| GOLDMAN SACHS GROUP INC (THE) | $63K | 13.10% |
| LEERINK PARTNERS LLC | $51K | 10.58% |
| CITIGROUP INC | $42K | 8.68% |
| BANK OF AMERICA CORPORATION | $40K | 8.22% |
| CONDOR TRADING LLC | $35K | 7.29% |
| MORGAN STANLEY | $34K | 6.96% |
| THE TORONTO DOMINION BANK | $32K | 6.65% |
| UBS GROUP AG | $26K | 5.32% |
FBTIX Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| JEFFERIES FINANCIAL GROUP INC | $24.0M | 35.55% |
| THE TORONTO DOMINION BANK | $17.8M | 26.32% |
| LEERINK PARTNERS LLC | $12.7M | 18.74% |
| GUGGENHEIM CAPITAL LLC | $6.3M | 9.27% |
| PIPER SANDLER COS | $5.2M | 7.68% |
| GOLDMAN SACHS GROUP INC (THE) | $1.1M | 1.59% |
| JPMORGAN CHASE and CO | $471K | 0.70% |
| MORGAN STANLEY | $99K | 0.15% |
Fidelity Advisor Biotechnology Fund Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| FIJYX | Class Z | 0.57% | none |
| FBTIX | Class I | 0.69% | none |
| FBTAX | Class A | 0.94% | 5.75% |
| FBTTX | Class M | 1.19% | 3.50% |
| FBTCX | Class C | 1.69% | none |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.